Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Amneal Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $391.9 million for Q2 2019.

• In Q2 2019, Long-Term Deferred Tax rose 4.86% year-over-year to $391.9 million; the TTM figure through Jun 2019 stood at $391.9 million (up 4.86% YoY), while the FY2018 annual figure was $373.2 million, up 41454.45% from the prior year.
• Long-Term Deferred Tax was $391.9 million for Q2 2019 at Amneal Pharmaceuticals, up from $382.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $391.9 million in Q2 2019 to a low of $898000.0 in Q4 2017.
• Historically, Long-Term Deferred Tax has averaged $314.8 million across 3 years, with a median of $373.4 million in 2018.
• The sharpest annual moves came in 2018 and 2019: Long-Term Deferred Tax soared 41454.45% in 2018, then advanced 4.86% in 2019.
• A 3-year view of Long-Term Deferred Tax shows it stood at $898000.0 in 2017, then jumped by 41454.45% to $373.2 million in 2018, then gained by 5.02% to $391.9 million in 2019.
• The last three Long-Term Deferred Tax figures came in at $391.9 million (Q2 2019), $382.9 million (Q1 2019), and $373.2 million (Q4 2018), per Business Quant data.